Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population
Year: 2026
Type: article
Study design: Observational Study
Source: Diabetic Medicine
DOI: 10.1111/dme.70208
Authors: Ashish Rai, James Marshall, Sampada Nandyala, Meg Her, Anna A. Agan, Ting‐Ying Huang, Carla Rodriguez‐Watson, Alecia Clary, Brandon Diessner, Margaret B. Nolan, Djeneba Audrey Djibo, Andrea DeVries, Kimberly Daniels, Xiao Zhang, Tongtong Wang, Ira Gantz, Ravi Shankar, Melissa MacCoy Zale, Precious Ejelonu, Robert Frederich, Urszula Masiukiewicz, Sengwee Toh
Institutions: Harvard University, Harvard Pilgrim Health Care, Reagan-Udall Foundation, Boston Biomedical (United States), Optibrium (United Kingdom), Intarcia Therapeutics (United States), Boston IVF, HealthPartners, CVS Health (United States), Humana (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Pfizer (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7128431746